Weight loss biotech plans IPO as demand builds for anti-obesity treatments
Aardvark Therapeutics’ drug has been shown in trials to suppress cravings in patients with rare genetic form of obesity
Full Article
Weight loss biotech plans IPO as demand builds for anti-obesity treatments
FT.com
0 shares
1 views
You might like
Related news coverage
Latest Weight-Loss Drug Faces Shortages
Latest Weight-Loss Drug , Faces Shortages .
The United States Food and Drug Administration
(FDA) says that high demand..
Wibbitz Top Stories